Advocacy intelligence hub — real-time data for patient organizations
Hospices Civils de Lyon — NA
ARCALYST: New indication approved
Arcalyst: FDA approved
Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Arcalyst
(rilonacept)Orphan drugKiniksa Pharmaceuticals, Ltd.
12.1 Mechanism of Action Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling b...
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Megace
(Megestrol acetate)Orphan drugstandardBristol-Myers Squibb Pharmaceutical Research Institute
Marcus Maurer, MD
Charite University, Berlin, Germany
📍 PUEBLO, CO
Hirsh D Komarow, M.D., M.D
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Robert Evans, PharmD.
Regeneron Pharmaceuticals
Dr Deven Parmar, MD
Cadila Healthcare Ltd.
Sara Alehashemi, M.D., MD
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Henrik Sonnergren, MD, PhD
Ventyx Biosciences, Inc
View all NLRP3-associated autoinflammatory disease specialists →